Recipharm has acquired OnTarget Chemistry for SEK 15.1 million, expanding its services into preclinical development services. OnTarget, based in Uppsala, Sweden specializes in medicinal chemistry offering synthesis and analytical services.
 
The preclinical chemistry services allow Recipharm to engage much earlier in customer projects. OnTarget’s synthesis capabilities will enhance the GMP development of APIs in Recipharm’s Italian subsidiary, Edmond Pharma.
 
Carl-Johan Spak, executive vice president of Development & Technology said, “With the acquisition of OnTarget Chemistry we will be able serve both existing and new customers with high quality development services. OnTarget Chemistry has a very skilled staff with a high number of PhDs working in a modern laboratory of very high standard. The acquisition is of strategic importance for Recipharm as it will together with the existing development organization fuel manufacturing sales in the long term.”
 
Fredrik Lehmann, chief executive officer of OnTarget Chemistry said, “The fit with Recipharm’s development organization is very good for us. We believe we can add preclinical competence and capabilities to Recipharm and we also look forward to contributing with a broad range of both local and international customers. This will be a great opportunity for us to continue to grow our business within Recipharm.”